Evidence map›Paper›PMID 31116639›Full record

ReviewJournal of neurophysiology2019

Impact of traumatic brain injury on amyotrophic lateral sclerosis: from bedside to bench.

Colin K Franz, Divya Joshi, Elizabeth L Daley, Rogan A Grant, Kyriakos Dalamagkas, Audrey Leung, John D Finan, Evangelos Kiskinis

Abstract readReview
In one paragraph

Review in Journal of neurophysiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Role of neuroinflammation in neurodegeneration development.Signal transduction and targeted therapy · 2023
    Review
  7. Review
  8. Article
  9. Article
  10. Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Colin K FranzBiologics Laboratory, Shirley Ryan AbilityLab, Chicago, Illinois.
Divya JoshiBiologics Laboratory, Shirley Ryan AbilityLab, Chicago, Illinois.
Elizabeth L DaleyThe Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Rogan A GrantThe Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Kyriakos DalamagkasDepartment of Physical Medicine and Rehabilitation, McGovern Medical School, TIRR Memorial Hermann, Houston, Texas.
Audrey LeungBiologics Laboratory, Shirley Ryan AbilityLab, Chicago, Illinois.
John D FinanDepartment of Neurosurgery, NorthShore University HealthSystem, Evanston, Illinois.
Evangelos KiskinisThe Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Funding

Determining How Defective Nucleo-Cytoplasmic Trafficking Leads To Neurodegeneration In C9orf72-Related ALS And FTDR01NS104219 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KISKINIS, EVANGELOS · 2018 to 2022
$2.3M
Defining The Impaired Proteostasis Network in ALS Patient Motor NeuronsR21NS107761 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KISKINIS, EVANGELOS, SAVAS, JEFFREY NICHOLAS · 2018 to 2019
$435k
Defining The Mechanisms by Which NEK1 Genetic Variants Associated with ALS Patient Motor Neurons Lead to Motor Neuron DegenerationR21NS111248 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KISKINIS, EVANGELOS · 2019 to 2019
$435k
A High Throughput, Human, In Vitro Model of Neuronal Stretch InjuryR21NS098129 · NINDS · ENDEAVOR HEALTH CLINICAL OPERATIONS · PI FINAN, JOHN D · 2017 to 2018
$429k
NINDS NIH HHS R01 NS104219NINDS NIH HHS R21 NS098129NINDS NIH HHS R21 NS107761NINDS NIH HHS R21 NS111248
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss of upper and lower motor neurons, which manifests clinically as progressive weakness. Although several epidemiological studies have found an association between traumatic brain injury (TBI) and ALS, there is not a consensus on whether TBI is an ALS risk factor. It may be that it can cause ALS in a subset of susceptible patients, based on a history of repetitive mild TBI and genetic predisposition. This cannot be determined based on clinical observational studies alone. Better preclinical models are necessary to evaluate the effects of TBI on ALS onset and progression. To date, only a small number of preclinical studies have been performed, mainly in the superoxide dismutase 1 transgenic rodents, which, taken together, have mixed results and notable methodological limitations. The more recent incorporation of additional animal models such as

Indexed as

Amyotrophic Lateral SclerosisBrain ConcussionDNA-Binding ProteinsInduced Pluripotent Stem CellsSuperoxide Dismutase-1AnimalsHumansDNA-Binding ProteinsSuperoxide Dismutase-1TARDBP protein, humanamyotrophic lateral sclerosis (ALS)concussioninduced pluripotent stem cell (iPSC)superoxide dismutase 1 (SOD1)TAR DNA-binding protein 43 (TDP-43)traumatic brain injury (TBI)

Identifiers

PMID31116639
PMCPMC6766734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.